Citations

Clear

861 citation(s) found for "Sd, Wexner".

Validating a Computable Phenotype for Nephrotic Syndrome in Children and Adults Using PCORnet Data
Oliverio, Andrea L. , Marchel, Dorota, Troost, Jonathan P. , Ayoub, Isabelle , Almaani, Salem , Greco, Jessica, Tran, Cheryl L., Denburg, Michelle R., Matheny, Michael E. , Dorn, Chad, Massengill, Susan F. , Desmond, Hailey, Greco, Jessica , Matheny, Michael , Gipson, Debbie S , Oliverio, Andrea L. , Marchel, Dorota, Troost, Jonathan P. , Ayoub, Isabelle , Almaani, Salem , Tran, Cheryl L., Denburg, Michelle R., Dorn, Chad, Massengill, Susan F. , Desmond, Hailey, Mariani, Laura H.

Mayo Clinic

Kidney360 | September 27, 2021 | Volume: 2 | Issue: 12 | Pages: 1979-1986

10.34067/kid.0002892021 | PMID 35419531 Get It

Key Points A computable phenotype combines routinely collected data elements from the EHR with logic elements to identify a condition of interest. This validated computable phenotype has strong classification characteristics to identify individuals with primary nephrotic syndrome. This computable phenotype for primary nephrotic syndrome can facilitate future research of these rare diseases. Background Primary nephrotic syndromes are rare diseases which can impede adequate sample size for observational patient-oriented research and clinical trial enrollment. A computable phenotype may be powerful in identifying patients with these diseases for research across multiple institutions. Methods A comprehensive algorithm of inclusion and exclusion ICD-9 and ICD-10 codes to identify patients with primary nephrotic syndrome was developed. The algorithm was executed against the PCORnet CDM at three institutions from January 1, 2009 to January 1, 2018, where a random selection of 50 cases and 50 noncases (individuals not meeting case criteria seen within the same calendar year and within 5 years of age of a case) were reviewed by a nephrologist, for a total of 150 cases and 150 noncases reviewed. The classification accuracy (sensitivity, specificity, positive and negative predictive value, F1 score) of the computable phenotype was determined. Results The algorithm identified a total of 2708 patients with nephrotic syndrome from 4,305,092 distinct patients in the CDM at all sites from 2009 to 2018. For all sites, the sensitivity, specificity, and area under the curve of the algorithm were 99% (95% CI, 97% to 99%), 79% (95% CI, 74% to 85%), and 0.9 (0.84 to 0.97), respectively. The most common causes of false positive classification were secondary FSGS (nine out of 39) and lupus nephritis (nine out of 39). Conclusion This computable phenotype had good classification in identifying both children and adults with primary nephrotic syndrome utilizing only ICD-9 and ICD-10 codes, which are available across institutions in the United States. This may facilitate future screening and enrollment for research studies and enable comparative effectiveness research. Further refinements to the algorithm including use of laboratory data or addition of natural language processing may help better distinguish primary and secondary causes of nephrotic syndrome.
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis
Garinis, Angela C. , Poling, Gayla L. , Konrad‐Martin, Dawn , Hullar, Timothy E. , Burrows, Holly , Chisholm, Jennifer , Custer, Amy , Hawe, Laura Dreisbach, Hunter, Lisa L. , Marras, Theodore K. , Ortiz, Candice E., Petersen, Lucretia , Winthrop, Kevin , Zettner, Erika M., Clark, Khaya D. , Hungerford, Michelle, Vachhani, Jay J., Brewer, Carmen C. , Steyger, Peter S , Clark, Khaya , Poling, Gayla L , Rubenstein, Ronald C. , Baguley, David

Mayo Clinic

American Journal of Audiology | September 22, 2021 | Volume: 30 | Issue: 3S | Pages: 800-809

10.1044/2021_aja-21-00031 | PMID 34549989 Get It

Purpose Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material https://doi.org/10.23641/asha.16624366
Use of adipose-derived stem cells in lymphatic tissue engineering and regeneration
Forte, Antonio J. , Boczar, Daniel , Sarabia-Estrada, Rachel , Huayllani, María T. , Ávila, Francisco R. , Guliyeva, Günel , Aung, Thiha , Quiñones‐Hinojosa, Alfredo , Torres, Ricardo A, Forte, Antonio Jorge , Sarabia-Estrada, Rachel , Avila, Francisco R , Torres‐Guzman, Ricardo A.

Mayo Clinic

Archives of Plastic Surgery | September 15, 2021 | Volume: 48 | Issue: 05 | Pages: 559-567

10.5999/aps.2021.00339 | PMID 34583446 Get It

The potential to differentiate into different cell lines, added to the easy and cost-effective method of extraction, makes adipose-derived stem cells (ADSCs) an object of interest in lymphedema treatment. Our study’s goal was to conduct a comprehensive systematic review of the use of ADSCs in lymphatic tissue engineering and regeneration. On July 23, 2019, using PubMed/MEDLINE, Cochrane Clinical Answers, Cochrane Central Register of Controlled Trials, and Embase databases, we conducted a systematic review of published literature on the use of ADSCs in lymphatic tissue engineering and regeneration. There were no language or time frame limitations, and the following search strategy was applied: ((Adipose stem cell) OR Adipose-derived stem cell)) AND ((Lymphedema) OR Breast Cancer Lymphedema). Only original research manuscripts were included. Fourteen studies fulfilled the inclusion criteria. Eleven studies were experimental (in vitro or in vivo in animals), and only three were clinical. Publications on the topic demonstrated that ADSCs promote lymphangiogenesis, and its effect could be enhanced by modulation of vascular endothelial growth factor-C, interleukin-7, prospero homeobox protein 1, and transforming growth factor-β1. Pilot clinical studies included 11 patients with breast cancer-related lymphedema, and no significant side effects were present at 12-month follow-up. Literature on the use of ADSCs in lymphatic tissue engineering and regeneration demonstrated promising data. Clinical evidence is still in its infancy, but the scientific community agrees that ADSCs can be useful in regenerative lymphangiogenesis. Data collected in this review indicate that unprecedented advances in lymphedema treatment can be anticipated in the upcoming years.
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression
Investigators, The Parkinson Study Group SURE-PD3, Bluett, Brent , Togasaki, Daniel M., Mihaila, Dragos, Evatt, Marian L., Rezak, Michael, Jain, Samay , Schwarzschild, Michael A. , Ascherio, Alberto, Casaceli, Cindy, Kamp, Cornelia , Lungu, Codrin , Oakes, David , Rudolph, Alice, Shoulson, Ira , Scott, B.L. , Gauger, Lisa, Aldred, Jason , Bixby, Melissa, Ciccarello, Jill, Gunzler, Steven A. , Henchcliffe, Claire , Brodsky, Matthew , Keith, Kellie, Hauser, Robert A. , LeDoux, Mark S. , Hinson, Vanessa K. , Kumar, Rajeev , Hunter, Christine , Christine, Chadwick W. , Daley, Aaron, Leehey, Maureen A. , Marcaida, Joy Antonelle de, Hung, Albert Y. , Bwala, Grace, Simon, David K. , Simuni, Tanya , Poon, Cynthia , Schiess, Mya C. , Park, Ariane , Peterson, Carolyn, Criswell, Susan R. , Durphy, Jennifer, Shill, Holly A. , Mehta, Shyamal H. , Deik, Andres , Fang, John Y., Stover, Natividad , Zhang, Lin , Dewey, Richard B. , Gerald, Ashley, Boyd, James T. , Houston, Emily , Suski, Valerie, Mosovsky, Sherri, Cloud, Leslie , Shah, Binit, James, Raymond , Zauber, S. Elizabeth , Reich, Stephen G. , Langhammer, April, LaFaver, Kathrin , Kaminski, Patricia L. , Goudreau, John L. , Russell, Doozie, Houghton, David , LaRoche, Ashley , Thomas, Karen , McGraw, Martha, Mari, Zoltan, Blindauer, Karen, Rabin, Marcie, Kurlan, Roger, Morgan, John C. , Ainslie, Melissa, Bódis-Wollner, Iván , Waters, Cheryl , Ratel, Amber Servi, Beck, Christopher A. , Bolger, Patrick, Callahan, Katherine F., Crotty, Grace F. , Klements, David , Kostrzebski, Melissa, McMahon, Gearoid M. , Pothier, Lindsay , Hauser, Robert A , Simuni, Tanya , Investigators, The Parkinson Study Group SURE-PD3, Curhan, Gary C. , Fitzgerald, Rebecca, Macklin, Eric A. , Marek, Kenneth , Mozaffarian, Dariush , Videnovic, Aleksandar , Goetz, Christopher G. , Espay, Alberto J. , Jimenez‐Shahed, Joohi , Friedman, Joseph H. , Litvan, Irene , Chou, Kelvin L. , Bhatti, Danish , Rosenthal, Liana S. , Ahmed, Anwar E. , Saint‐Hilaire, Marie , Shprecher, David , Pahwa, Rajesh , LeWitt, Peter A. , Kaminski, Patricia, Thomas, Karen, Serrano, Carmen , Soileau, Michael J , Schneider, Ruth B. , Waikar, Sushrut S. , Lang, Anthony E. , Mestre, Tiago

Mayo Clinic

JAMA | September 14, 2021 | Volume: 326 | Issue: 10 | Pages: 926

10.1001/jama.2021.10207 | PMID 34519802 Get It

Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma
Ramírez-Loera, Cristopher , Malouff, Timothy D. , Seneviratne, Danushka S. , Palmer, Joshua D. , Ramirez-Loera, Cristopher , Palmer, Joshua D , Ruiz-García, Henry , Trifiletti, Daniel M.

Mayo Clinic

International Journal of Molecular Sciences | September 7, 2021 | Volume: 22 | Issue: 18 | Pages: 9673

10.3390/ijms22189673 | PMID 34575840 Get It

Radiotherapy (RT) is one of the cornerstones in the current treatment paradigm for glioblastoma (GBM). However, little has changed in the management of GBM since the establishment of the current protocol in 2005, and the prognosis remains grim. Radioresistance is one of the hallmarks for treatment failure, and different therapeutic strategies are aimed at overcoming it. Among these strategies, nanomedicine has advantages over conventional tumor therapeutics, including improvements in drug delivery and enhanced antitumor properties. Radiosensitizing strategies using nanoparticles (NP) are actively under study and hold promise to improve the treatment response. We aim to describe the basis of nanomedicine for GBM treatment, current evidence in radiosensitization efforts using nanoparticles, and novel strategies, such as preoperative radiation, that could be synergized with nanoradiosensitizers.
Incorporation of Social Risk in US Preventive Services Task Force Recommendations and Identification of Key Challenges for Primary Care
Davidson, Karina W. , Krist, Alex H. , Tseng, Chien‐Wen , Kemper, Alex R. , Kubik, Martha , Ngo‐Metzger, Quyen, Mills, Justin, Doubeni, Chyke A. , Krist, Alex , Davidson, Karina , Simon, Melissa Andrea , Borsky, Amanda E.

Mayo Clinic

JAMA | September 1, 2021 | Volume: 326 | Issue: 14 | Pages: 1410

10.1001/jama.2021.12833 | PMID 34468692 Get It

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Shah, Pankil , Rubinstein, Samuel M. , Joyner, Michael J. , Choueiri, Toni K. , Flora, Daniel , Gulati, Anthony P., Koshkin, Vadim S. , Papadopoulos, Esperanza B. , Robilotti, Elizabeth , Su, Christopher , Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Yu, Peter Paul , Mishra, Sanjay , Senefeld, Jonathon W. , Shah, Dimpy P. , Verma, Amit , Gartrell, Benjamin A. , Ohri, Nitin , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bohachek, Pamela, Mundt, Daniel , Streckfuss, Mitrianna, Tadesse, Eyob, Lammers, Philip E. , Revankar, Sanjay G. , Khan, Hina, Prete, Salvatore A. Del , Angevine, Anne H., Bär, Michael , Lo, KM Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Nakayama, John , Gupta, Shilpa , Ahluwalia, Manmeet S. , Dawsey, Scott J. , Nizam, Amanda , Lemmon, Christopher A. , Hoppenot, Claire , Bakouny, Ziad , Bouchard, Gabrielle, Busser, Fiona, Conners, Jean M, Curran, Catherine , Demetri, George D., Kelleher, Kaitlin M. , Shaw, Grace, Nuzzo, Pier Vitale , Zon, Rebecca L. , Zhang, Tian , Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Tachiki, Lisa ML, Vinayak, Shaveta , Wagner, Michael J. , Yeh, Albert C. , Goyal, Sharad , Clément, Jessica , Daher, Ahmad , Dailey, Mark E., Hsu, Emily , Menendez, Alvaro G. , Rathmann, Joerg, Serrano, Oscar K. , Jayaraj, Asha, Accordino, Melissa , Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Shafer, Danielle , Lewis, Mark A. , Rhodes, Terence D., Gill, David , Low, Clarke A., Nagle, Sarah , Hayes‐Lattin, Brandon , Nemecek, Eneida R. , Zaren, Howard A. , Smith, Stephanie J., Akhtari, Mojtaba, Lau, Eric , Reeves, Mark E. , Elms, Destry, Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Shah, Surbhi, Rosovsky, Rachel , Reynolds, Kerry L. , Bardia, Aditya , Gainor, Justin F. , Zubiri, Leyre , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Belenkaya, Rimma , Riely, Gregory J. , Faller, Bryan A. , McKay, Rana R. , Ajmera, Archana , Cabal, Angelo , Shaya, Justin , Weissmann, Lisa B., Jani, Chinmay , Chen, James L. , Jhawar, Sachin R, Lustberg, Maryam B. , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Karivedu, Vidhya , Addison, Daniel , Menon, Harry, Rovito, Marc A., Elshoury, Amro, Shah, Mansi , Mahmood, Sana , Mico, Vasil, Rivera, Andrea Verghese, Miller, Chaim , Cabebe, Elwyn C., Glover, Michael , Jha, Alokkumar , Schapira, Lidia , Shah, Sumit , Subbiah, Suki , Logan, Barbara, Lopes, Gilberto , Russell, Karen , Stith, Brittany, Smits, Melissa, Edwin, Natasha, Chism, David D. , Owenby, Susie, Doroshow, Deborah B. , Galsky, Matthew D. , Zhu, Huili , Fu, Julie , Patel, Kanishka G. , Riess, Jonathan W. , Kwon, Daniel H. , Islam, Jessica Y. , Ahmad, Syed A. , Grover, Punita , Kharofa, Jordan , Marcum, Michelle, Park, Cathleen, Geiger, Christopher L., Bishnoi, Rohit , Feldman, Lawrence , Hoskins, Kent , Gantt, Gerald, Khan, Mahir, Nguyen, Ryan H, Schwartz, Candice, Venepalli, Neeta K. , Kasi, Anup , Fecher, Leslie A. , Mavromatis, Blanche H., Bijjula, Ragneel R., Cheng, Alex , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Reid, Sonya , Slosky, David, Solórzano, Carmen C. , Vega-Luna, Karen, Enriquez, Kyle T. , Sun, Tianyi , Carducci, Theresa M., Puc, Matthew , Loon, Susan Van, Goldsmith, Karen J., Rice, Robert, Cabalona, Wilhelmina D., Pilar, Christine, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Bilen, Mehmet Asım , Ravindranathan, Deepak , LoRusso, Patricia , Masters, Tyler, Choueiri, Toni K , Bakouny, Ziad , Mishra, Sanjay , Yeh, Albert C , Xie, Zhuoer , Zubiri, Leyre , Su, Christopher , Fiala, Mark A , Joyner, Michael J , Senefeld, Jonathon W , Ahluwalia, Manmeet S , Lustberg, Maryam , Thompson, Michael A. , Henderson, Jeffrey P. , Griffiths, Elizabeth A. , Hwang, Clara , Warner, Jeremy L. , Halmos, Balázs , Goel, Sanjay , Sica, Roberto Alejandro , Thakkar, Astha , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Panagiotou, Orestis A. , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Loaiza‐Bonilla, Arturo , Bar, Michael H, Lo, K. M. Steve, Caimi, Paolo F. , Barnholtz‐Sloan, Jill S. , Pennell, Nathan A , Li, Ang , Giordano, Antonio , Nohria, Anju , Schmidt, Andrew , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Lyman, Gary H , Graber, Jerome J. , Khaki, Ali Raza , Loggers, Elizabeth T , Nakasone, Elizabeth S. , Tachiki, Lisa M, Gatson, Na Tosha , Huynh‐Le, Minh‐Phuong , Rosenstein, Lori J. , Elias, Rawad , Gadgeel, Shirish M. , Hawley, Jessica E. , Hershman, Dawn L. , Bhutani, Divaya , Schwartz, Gary K. , Reuben, Daniel Y. , McWeeney, Shannon K. , Nagaraj, Gayathri , Berg, Stephanie , Morgans, Alicia K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Boland, Genevieve M. , Hálfdánarson, Þorvarður R. , Bekaii‐Saab, Tanios , Desai, Aakash , Mesa, Ruben A. , Ramirez, Amelie G , Philip, John , Gatti-Mays, Margaret Elena , Jhawar, Sachin R, Palmer, Joshua D. , Stover, Daniel G. , Joshi, Monika , Jabbour, Salma K , Bashir, Babar , McNair, Christopher M. , Wu, Julie , Kloecker, Goetz Hans , Fazio, Alyson, Kumar, Vaibhav , Wood, William A. , Gulati, Shuchi , Wise-Draper, Trisha Michel , Bowles, Daniel W. , Markham, Merry Jennifer , Shah, Chintan , Acoba, Jared David , Rho, Young Soo, Nguyen, Ryan H, Pasquinelli, Mary M. , Vikas, Praveen , Friese, Christopher R. , Zaman, Qamar U, Davis, Elizabeth J. , Hausrath, Daniel J. , Hsu, Chih–Yuan , Li, Xuanyi , Rini, Brian I. , Shyr, Yu , Tucker, Matthew D. , Wang, Lucy Lu , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Oncology | August 19, 2021 | Volume: 7 | Issue: 8 | Pages: 1167

10.1001/jamaoncol.2021.1799 | PMID 34137799 Get It

A model of weight‐based stigma in health care and utilization outcomes: Evidence from the learning health systems network
Phelan, Sean M. , Haller, Irina V. , Schroeder, Darrell R. , Fischer, Kristin , Croghan, Ivana T. , Croghan, Ivana, Phelan, S M , Schroeder, Darrell , Bauer, Katherine W. , Bradley, David , Bradley, Steven M. , Mundi, Manpreet S. , Rutten, Lila J. Finney

Mayo Clinic

Obesity Science & Practice | August 17, 2021 | Volume: 8 | Issue: 2 | Pages: 139-146

10.1002/osp4.553 | PMID 35388341 Get It

AbstractObjectiveObesity is stigmatized and people with obesity report experiencing stigmatizing situations when seeking health care. The implications of these experiences are not well understood. This study tests an indirect effects model of negative care experiences as an intermediate variable between obesity and care avoidance/utilization and switching primary care doctors.MethodsA survey was completed by 2380 primary care patients in the Learning Health Systems Network (LHSNet) Clinical Data Research Network with a BMI >25 kg/m2. Measures included scales assessing stigmatizing situations, perceived patient‐centered communication, perceived respect, having delayed needed care, and having looked for a new primary doctor in the past 12 months. Sequential and serial indirect effects of care experiences and respect in the association between BMI and care utilization outcomes was modeled.ResultsThe hypothesized model was supported by findings. The associations between BMI and delaying needed care (OR = 1.06, p < 0.001) and attempting to switch primary doctors (OR = 1.02, p = 0.04) was mediated by both stigmatizing situations experienced in a health care context and lower patient‐centered communication. Lower perceived respect mediated the association between care experiences and utilization outcomes.ConclusionsPeople with higher BMIs may avoid care or switch doctors as a result of stigmatizing experiences and poor communication with doctors. These outcomes may contribute to morbidity in people with obesity if they delay or avoid care for health concerns when symptoms first present.